| |
Univariable Cox regression model
|
Multivariable Cox regression model 1
|
Multivariable Cox regression model 2
|
|---|
| |
HR (95% CI)
|
P value
|
HR (95% CI)
|
P value
|
HR (95% CI)
|
P value
|
|---|
|
Primary endpoint: cardiac death
|
|
Per 1%/increasea
|
0.904 (0.858–0.952)
|
P < 0.001
|
0.887 (0.834–0.944)
|
P < 0.001
|
0.897 (0.844–0.954)
|
P = 0.001
|
|
≥11.0% group vs < 11.0% group
|
0.280 (0.154–0.509)
|
P < 0.001
|
0.239 (0.124–0.460)
|
P < 0.001
|
0.273 (0.142–0.526)
|
P < 0.001
|
|
Secondary endpoint: all-cause mortality
|
|
Per 1%/increasea
|
0.886 (0.848–0.926)
|
P < 0.001
|
0.880 (0.836–0.926)
|
P < 0.001
|
0.888 (0.844–0.933)
|
P < 0.001
|
|
≥11.0% group vs < 11.0% group
|
0.276 (0.170–0.449)
|
P < 0.001
|
0.277 (0.163–0.469)
|
P < 0.001
|
0.299 (0.177–0.505)
|
P < 0.001
|
- Multivariable Cox regression model 1 was adjusted for age at implantation, sex, BMI, LVEF, LVEDD, ICD or CRT-D implantation, NYHA Class, hypertension, DM, stroke, DCM, ICM, MI, PCI, pre-implant syncope, prior AF, use of ACEIs/ARBs, use of diuretics, and use of aldosterone antagonists. Multivariate Cox regression model 2 was adjusted for the above-mentioned confounders and additional HRV
- ACEIs/ARBs angiotensin-converting enzyme inhibitors or angiotensin receptor blockers, AF atrial fibrillation, BMI body mass index, CI confidence interval, CRT-D cardiac resynchronisation therapy defibrillator, DM diabetic mellitus, HRV heart rate variability, HR hazard ratio, ICD implantable cardioverter defibrillator, ICM ischaemic cardiomyopathy, LVEF left ventricular ejection fraction, LVEDD left ventricular end-diastolic dimension, MI myocardial infarction, NYHA New York Heart Association, PA physical activity, PCI percutaneous coronary intervention
- a each additional 1% increase in PA
